Clinical Trials Logo

Primary Biliary Cholangitis clinical trials

View clinical trials related to Primary Biliary Cholangitis.

Filter by:

NCT ID: NCT05133336 Recruiting - Clinical trials for Primary Biliary Cholangitis

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

EPICS-III
Start date: April 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Saroglitazar Magnesium 1 mg and 2 mg tablets for treatment of subjects with Primary Biliary Cholangitis (PBC)

NCT ID: NCT05104853 Active, not recruiting - Clinical trials for Primary Biliary Cholangitis

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

Start date: January 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.

NCT ID: NCT05050136 Recruiting - Clinical trials for Primary Biliary Cholangitis

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

VANTAGE
Start date: September 22, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.

NCT ID: NCT05014672 Active, not recruiting - Clinical trials for Primary Biliary Cholangitis

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

TRANSFORM
Start date: February 14, 2022
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the effect of setanaxib on alkaline phosphatase (ALP) at Week 24 in participants with PBC and with elevated liver stiffness and intolerance or inadequate response to ursodeoxycholic acid (UDCA).

NCT ID: NCT04950764 Recruiting - Hepatic Impairment Clinical Trials

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Start date: September 17, 2021
Phase: Phase 1
Study type: Interventional

The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

NCT ID: NCT04650243 Recruiting - Clinical trials for Primary Biliary Cholangitis

Clinical Research of UCDA Reducing Medication Regimen in Stable PBC

UCDA PBC
Start date: March 21, 2020
Phase: Phase 4
Study type: Interventional

This study explores the feasibility of the reducing medication regimen for Ursodeoxycholic Acid(UDCA) in the treatment of primary biliary cholangitis. The participants will be distributed randomly into two experimental groups and one control group. The two experimental groups will receive reduced dosage of UDCA at different level, while the control group will receive standard dosage of UDCA. The effect of therapy will be evaluated every three months.

NCT ID: NCT04620733 Completed - Clinical trials for Primary Biliary Cholangitis

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Start date: April 21, 2021
Phase: Phase 3
Study type: Interventional

To evaluate the treatment effect of seladelpar on composite biochemical improvement in cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar over 12 months of treatment compared to placebo

NCT ID: NCT04618575 Recruiting - Hepatitis Clinical Trials

Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1

Start date: March 17, 2021
Phase: Phase 4
Study type: Interventional

A randomized controlled open-label clinical trial of ursodeoxycholic acid combined with total glucosides of paeony in the treatment of PBC with AIH features 1

NCT ID: NCT04617561 Recruiting - Clinical trials for Primary Biliary Cholangitis

Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II

Start date: November 1, 2020
Phase: Phase 4
Study type: Interventional

A randomized controlled open-label clinical trial of ursodeoxycholic acid combined with low dose glucocorticoid in the treatment of PBC With AIH Features II to asses efficacy and safety.

NCT ID: NCT04604652 Completed - Clinical trials for Primary Biliary Cirrhosis

Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis

PRONTO-PBC
Start date: May 27, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this open-label study is to evaluate the safety and tolerability of HDT1801 (BUDCA) over 12 weeks in adult subjects with PBC who have an inadequate response to standard therapy. Inadequate response is defined as persistently elevated serum alkaline phosphatase at greater than or equal to1.5 times the upper limits of normal for the testing lab in spite of having been on adequate doses of standard therapy with UDCA (ursodeoxycholic acid) at 13-15 mg/kg for at least 6 months.